127 related articles for article (PubMed ID: 33974884)
21. A systematic review of hypofractionation for primary management of prostate cancer.
Koontz BF; Bossi A; Cozzarini C; Wiegel T; D'Amico A
Eur Urol; 2015 Oct; 68(4):683-91. PubMed ID: 25171903
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen bounce after high-dose-rate prostate brachytherapy and hypofractionated external beam radiotherapy.
Patel N; Souhami L; Mansure JJ; Duclos M; Aprikian A; Faria S; David M; Cury FL
Brachytherapy; 2014; 13(5):450-5. PubMed ID: 25023396
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcomes of moderately hypofractionated radiotherapy (67.5 Gy in 25 fractions) for prostate cancer confined to the pelvis: a single center retrospective analysis.
Yao L; Shou J; Wang S; Song Y; Fang H; Lu N; Tang Y; Chen B; Qi S; Yang Y; Jing H; Jin J; Yu Z; Li Y; Liu Y
Radiat Oncol; 2020 Oct; 15(1):231. PubMed ID: 33008404
[TBL] [Abstract][Full Text] [Related]
24. Implementation of hypofractionated prostate radiation therapy in the United States: A National Cancer Database analysis.
Stokes WA; Kavanagh BD; Raben D; Pugh TJ
Pract Radiat Oncol; 2017; 7(4):270-278. PubMed ID: 28673554
[TBL] [Abstract][Full Text] [Related]
25. The Financial Impact on Reimbursement of Moderately Hypofractionated Postoperative Radiation Therapy for Breast Cancer: An International Consortium Report.
Marta GN; Ramiah D; Kaidar-Person O; Kirby A; Coles C; Jagsi R; Hijal T; Sancho G; Zissiadis Y; Pignol JP; Ho AY; Cheng SH; Offersen BV; Meattini I; Poortmans P
Clin Oncol (R Coll Radiol); 2021 May; 33(5):322-330. PubMed ID: 33358283
[TBL] [Abstract][Full Text] [Related]
26. The Impact of Radiation Oncologists on the Early Adoption of Hypofractionated Radiation Therapy for Early-Stage Breast Cancer.
Boero IJ; Gillespie EF; Hou J; Paravati AJ; Kim E; Einck JP; Yashar C; Mell LK; Murphy JD
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):571-580. PubMed ID: 28126306
[TBL] [Abstract][Full Text] [Related]
27. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
Abu-Gheida I; Reddy CA; Kotecha R; Weller MA; Shah C; Kupelian PA; Mian O; Ciezki JP; Stephans KL; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):325-333. PubMed ID: 30721720
[TBL] [Abstract][Full Text] [Related]
28. Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer.
Osti MF; Agolli L; Valeriani M; Falco T; Bracci S; De Sanctis V; Enrici RM
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e157-63. PubMed ID: 23182393
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer.
Teh BS; Lewis GD; Mai W; Pino R; Ishiyama H; Butler EB
Cancer Commun (Lond); 2018 Apr; 38(1):11. PubMed ID: 29764515
[TBL] [Abstract][Full Text] [Related]
30. Radical radiotherapy for prostate cancer: patterns of care in Sweden 1998-2016.
Beckmann K; Garmo H; Nilsson P; Franck Lissbrant I; Widmark A; Stattin P
Acta Oncol; 2020 May; 59(5):549-557. PubMed ID: 32122185
[No Abstract] [Full Text] [Related]
31. Ten-Year Outcomes of Moderately Hypofractionated Salvage Postprostatectomy Radiation Therapy and External Validation of a Contemporary Multivariable Nomogram for Biochemical Failure.
Chin S; Fatimilehin A; Walshaw R; Argarwal A; Mistry H; Elliott T; Logue J; Wylie J; Choudhury A
Int J Radiat Oncol Biol Phys; 2020 Jun; 107(2):288-296. PubMed ID: 31987961
[TBL] [Abstract][Full Text] [Related]
32. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer.
Johnson SB; Soulos PR; Shafman TD; Mantz CA; Dosoretz AP; Ross R; Finkelstein SE; Collins SP; Suy S; Brower JV; Ritter MA; King CR; Kupelian PA; Horwitz EM; Pollack A; Abramowitz MC; Hallman MA; Faria S; Gross CP; Yu JB
Radiother Oncol; 2016 Nov; 121(2):294-298. PubMed ID: 27890426
[TBL] [Abstract][Full Text] [Related]
33. Hypofractionated radiotherapy recommendations for localized prostate cancer in Brasil.
Palhares DMF; Pimentel LCF; Castilho MS; Costa ABD; Reisner ML; Kuhnen FQ; Pássaro A; Leite ETT; Faustino FLC; Obst FM; Costa FNBBF; Pioner GT; Carvalho ÍT; Silva JLFD; Morikawa LKK; Zanuncio PHDR; Hanriot RM; Rosa AA
Rev Assoc Med Bras (1992); 2021 Jan; 67(1):7-18. PubMed ID: 34161478
[TBL] [Abstract][Full Text] [Related]
34. Hypofractionated Radiotherapy for Localized Prostate Cancer: When and for Whom?
Roy S; Morgan SC
Curr Urol Rep; 2019 Jul; 20(9):53. PubMed ID: 31359187
[TBL] [Abstract][Full Text] [Related]
35. Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial.
Arcangeli G; Saracino B; Arcangeli S; Gomellini S; Petrongari MG; Sanguineti G; Strigari L
J Clin Oncol; 2017 Jun; 35(17):1891-1897. PubMed ID: 28355113
[TBL] [Abstract][Full Text] [Related]
36. Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients.
Nicosia L; Mazzola R; Rigo M; Figlia V; Giaj-Levra N; Napoli G; Ricchetti F; Corradini S; Ruggieri R; Alongi F
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2547-2554. PubMed ID: 31324979
[TBL] [Abstract][Full Text] [Related]
37. Trends and Patterns of Utilization of Hypofractionated Postmastectomy Radiotherapy: A National Cancer Database Analysis.
Venigalla S; Guttmann DM; Jain V; Sharma S; Freedman GM; Shabason JE
Clin Breast Cancer; 2018 Oct; 18(5):e899-e908. PubMed ID: 29550285
[TBL] [Abstract][Full Text] [Related]
38. Moderately HRT vs. CRT for localized prostate cancer using image-guided VMAT with SIB: evaluation of acute and late toxicities.
Vassis S; Nöldeke B; Christiansen H; von Klot CA; Merten R
Strahlenther Onkol; 2020 Jul; 196(7):598-607. PubMed ID: 32040691
[TBL] [Abstract][Full Text] [Related]
39. Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis.
Tamihardja J; Schortmann M; Lawrenz I; Weick S; Bratengeier K; Flentje M; Guckenberger M; Polat B
Strahlenther Onkol; 2021 Feb; 197(2):124-132. PubMed ID: 32833036
[TBL] [Abstract][Full Text] [Related]
40. Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study.
Jorgo K; Polgar C; Major T; Stelczer G; Herein A; Pocza T; Gesztesi L; Agoston P
Pathol Oncol Res; 2020 Apr; 26(2):905-912. PubMed ID: 30888646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]